• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Momtazee James C

    10/4/21 5:13:02 PM ET
    $MAAC
    Business Services
    Finance
    Get the next $MAAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    MOMTAZEE JAMES C

    (Last) (First) (Middle)
    C/O MONTES ARCHIMEDES ACQUISITION CORP.
    2884 SAND HILL ROAD, SUITE 100

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Montes Archimedes Acquisition Corp [ MAAC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/30/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    The reporting person resigned immediately prior to the business combination and ceased to be a reporting person with respect to the issuer.
    /s/ James C. Momtazee 10/01/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MAAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MAAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MAAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patient Square Capital Llc

    4 - Montes Archimedes Acquisition Corp (0001819263) (Issuer)

    10/4/21 5:20:05 PM ET
    $MAAC
    Business Services
    Finance

    SEC Form 4 filed by Walker Maria C

    4 - Montes Archimedes Acquisition Corp (0001819263) (Issuer)

    10/4/21 5:13:55 PM ET
    $MAAC
    Business Services
    Finance

    SEC Form 4 filed by Oesterle Stephen N.

    4 - Montes Archimedes Acquisition Corp (0001819263) (Issuer)

    10/4/21 5:13:42 PM ET
    $MAAC
    Business Services
    Finance

    $MAAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing

    Roivant will begin trading on Nasdaq under the ticker "ROIV" later todayR&D Day presentations from September 28th highlighting Roivant's pipeline and discovery platform available on Roivant's investor page BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has closed its business combination with Montes Archimedes Acquisition Corp. (NASDAQ:MAAC), a special purpose acquisition company, as well as a concurrent PIPE financing. Outstanding shares and warrants of MAAC have been exchanged for newly issued Roivant shares and w

    10/1/21 8:00:00 AM ET
    $MAAC
    Business Services
    Finance

    Roivant Provides Corporate Updates

    NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange, have signed a definitive merger agreement. The combined entity, to be named Datavant, will be the nation's largest health data ecosystem, enabling patients, providers, payers, health data analytics companies, patient-facing applications, government agencies, and life science companies to securely exchange their patient-level data. The combined company will have an enterprise value of $7 billion. The merger is subject to typical regulatory approvals and is

    6/9/21 7:40:00 AM ET
    $MAAC
    Business Services
    Finance

    Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology

    NEW YORK, MENLO PARK, Calif., LONDON, and BASEL, Switzerland, May 3, 2021 /PRNewswire/ -- Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (NASDAQ:MAAC), a special purpose acquisition company sponsored by Patient Square Capital, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, outstanding shares and warrants of MAAC will be exchanged for newly issued shares and warrants of Roivant Sciences, which is expected to be listed on Nasdaq under the new ticker symbol "ROIV." The transaction is expected to deliver up to $611 million of gross proceeds to fund discover

    5/3/21 7:00:00 AM ET
    $MAAC
    Business Services
    Finance

    $MAAC
    SEC Filings

    View All

    SEC Form 15-12B filed by Montes Archimedes Acquisition Corp.

    15-12B - Montes Archimedes Acquisition Corp (0001819263) (Filer)

    10/12/21 8:30:50 AM ET
    $MAAC
    Business Services
    Finance

    SEC Form 25-NSE filed by Montes Archimedes Acquisition Corp.

    25-NSE - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    9/30/21 4:11:17 PM ET
    $MAAC
    Business Services
    Finance

    Montes Archimedes Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Montes Archimedes Acquisition Corp (0001819263) (Filer)

    9/29/21 7:58:17 AM ET
    $MAAC
    Business Services
    Finance

    $MAAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Montes Archimedes Acquisition Corp. (Amendment)

    SC 13G/A - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    10/12/21 11:51:38 AM ET
    $MAAC
    Business Services
    Finance

    SEC Form SC 13G filed by Montes Archimedes Acquisition Corp.

    SC 13G - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    9/27/21 5:14:37 PM ET
    $MAAC
    Business Services
    Finance

    SEC Form SC 13G filed

    SC 13G - Montes Archimedes Acquisition Corp (0001819263) (Subject)

    2/26/21 5:15:27 PM ET
    $MAAC
    Business Services
    Finance